B-cell lymphoma is a cancer of the B lymphocytes, a type of cell that forms part of the immune system. Lymphomas are “blood cancers” in lymphoid organs.
B-cell lymphoma is the most common form of hematological malignancy, or “blood cancer,” in the United States. Taken together, lymphomas represent 5.0 % of all cancers in the United States and 55 % of all blood cancers. B-cell lymphomas express B-cell receptor (BCR) (membrane bound antibody) on their surface and B-cell lineage specific markers such as CD19 and CD20. B lymphoma cells often originate in lymph nodes, presenting as an enlargement of the node (a tumor). There are neither early warning signs nor known effective genetic or biochemical markers that can be used for screening purposes. There are two types of B cell lymphomas – Hodgkin’s lymphoma (HL) and Non-Hodgkin’s lymphoma (NHL), which differ in the morphology and phenotype of lymphoma cells and the...
KeywordsChronic Lymphocytic Leukemia Follicular Lymphoma Mantle Cell Lymphoma Burkitt Lymphoma Gastric Lymphoma
- Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O’Brien S (2015) Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125(16):2497–2506Google Scholar